-
Mashup Score: 8The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma- A review of the literature - 2 month(s) ago
Paraneoplastic neurological syndromes (PNS) are rare neurological disorders arising from malignancy-triggered autoimmunity, yet their association with…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1
Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC), Meet-URO score, ZEBRA Study (Meet-URO 9), Cabozantinib, vascular endothelial growth factor (VEGF) inhibitors, metastatic renal cell carcinoma treatment, ZEBRA/Meet-URO-9 study, nivolumab, ipilimumab, IMDC score.
Source: www.urotoday.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 0Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study - 2 month(s) ago
Scientific Reports – Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1
Watch this videoclip from the Monty Pal presentation at #IUCS23 titled “How to choose first-line therapy for mRCC”
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1
Watch this videoclip from the Monty Pal presentation at #IUCS23 titled “How to choose first-line therapy for mRCC”
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 8
Original Article from The New England Journal of Medicine — Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Source: www.nejm.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 17Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Lung Cancer - 4 month(s) ago
This randomized clinical trial compares progression-free survival using treatment with atezolizumab plus carboplatin with pemetrexed vs atezolizumab, carboplatin with pemetrexed, and bevacizumab in patients with non–small cell lung cancer.
Source: jamanetwork.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 29
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet-
Nice @JCO_ASCO editorial on #PARPi combinations in 1st line #mCRPC #prostatecancer, but let's address some barriers: 1. Real-world access to #BRCA & #HRR testing needs improvement for #PARPi use 2. Regardless of #HRR status, we've shown pooled OS benefit https://t.co/fKjqk1qTNR https://t.co/FcsUAjFJDr
-
-
Mashup Score: 6Molecular Testing in Non–Small-Cell Lung Cancer: A Call to Action - 5 month(s) ago
It has been nearly 15 years since the IPASS trial first demonstrated the importance of molecular testing to identify the population of patients with non–small-cell lung cancer (NSCLC) that benefit from molecularly targeted therapy. 1 Molecular genomic testing has become more widespread since then, with an increasing number of molecular targets and molecularly targeted therapies. As many as 50% of patients with advanced NSCLC are found to have an actionable oncogenic driver (including KRAS mutations). 2
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1
Watch this videoclip from the Gopi Gnanasegaran presentation at #IUCS23 titled “Theragnostics in mPCa: Diagnosis and Treatment”
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet
Delving into the link between Paraneoplastic Neurological Syndromes (PNS) and Urothelial Carcinoma 🧠🔬https://t.co/gjoEcqcpEj 📑 Rare yet significant connection, predominantly in elderly women w cerebellar syndromes Immunomodulation + tumor resection show promise. @ManiamAkash https://t.co/i7LpXTuHqi